https://orcid.org/0000-0001-8253-2411
References
- Dudal S , BaltrukonisD , CrisinoRet al. Assay formats: recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team. AAPS J.16, 194–205 (2014).
- Patel SR , BryanP , SpoonerN , TimmermanP , WickremsinheE. Microsampling for quantitative bioanalysis, an industry update: output from an AAPS/EBF survey. Bioanalysis11(7), 619–628 (2019).
- Fischer SK , JoyceA , SpenglerMet al. Emerging technologies to increase ligand binding assay sensitivity. AAPS J.17(1), 93–101 (2015).
- Roman J , QiuJ , DornadulaG , HamuroL , BakhtiarR , VerchT. Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis. J. Pharmacol. Toxicol. Methods63(3), 227–235 (2011).
- Leary BA , Lawrence-HendersonR , MallozziCet al. Bioanalytical platform comparison using a generic human IgG PK assay format. J. Immunol. Methods397(1–2), 28–36 (2013).
- Duo J , BrunoJ , KozhichAet al. Surface plasmon resonance as a tool for ligand-binding assay reagent characterization in bioanalysis of biotherapeutics. Bioanalysis10(8), 559–576 (2018).
- Spengler M , AdlerM , NiemeyerCM. Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques. Analyst140(18), 6175–6194 (2015).
- Lind K , KubistaM. Development and evaluation of three real-time immuno-PCR assemblages for quantification of PSA. J. Immunol. Methods304(1–2), 107–116 (2005).
- Attallah C , RodríguezMC , LozanoV , EtcheverrigarayM , OggeroM. Design and validation of an immuno-PCR assay for IFN-α2b quantification in human plasma. Bioanalysis11(23), 2175–2188 (2019).
- Woodbury N , BaldE , GeistB , YangT-Y. Application of multiplexed pharmacokinetic immunoassay to quantify in vivo drug forms and coadministered biologics. Bioanalysis11(24), 2251–2268 (2019).
- Stevenson LF , PurushothamaS. Parallelism: considerations for the development, validation and implementation of PK and biomarker ligand-binding assays. Bioanalysis6(2), 185–198 (2014).
- Lee JW , DevanarayanV , BarrettYCet al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res.23(2), 312–328 (2006).
- Stevenson L , KelleyM , GorovitsBet al. Large molecule specific assay operation: recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team. AAPS J.16(1), 83–88 (2014).
- Desilva B , SmithW , WeinerRet al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res.20(11), 1885–1900 (2003).
- Lee JW , KelleyM , KingLEet al. Bioanalytical approaches to quantify ‘total’ and ‘free’ therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J.13(1), 99–110 (2011).
- Fandozzi C , EvansC , WilsonAet al. 2019 White paper on recent issues in bioanalysis: chromatographic assays (part 1 – innovation in small molecules and oligonucleotides & mass spectrometric method development strategies for large molecule bioanalysis). Bioanalysis11(22), 2029–2048 (2019).
- Pearson JT , RockDA. Bioanalytical approaches to assess the proteolytic stability of therapeutic fusion proteins. Bioanalysis7(23), 3035–3051 (2015).
- Vasicek LA , ZhuX , SpellmanDS , BatemanKP. Direct quantitation of therapeutic antibodies for pharmacokinetic studies using immuno-purification and intact mass analysis. Bioanalysis11(3), 203–213 (2019).